Erasca, Inc.
Clinical trials sponsored by Erasca, Inc., explained in plain language.
-
New hope for hard-to-treat melanoma: drug duo targets NRAS mutation
Disease control OngoingThis study tests whether a combination of two drugs (naporafenib and trametinib) works better than standard treatments for people with advanced NRAS-mutant melanoma that has already been treated. About 78 adults with this specific type of skin cancer will take part. The goal is t…
Phase: PHASE3 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 26, 2026 06:18 UTC
-
New drug duo targets hard-to-treat cancers with RAS mutation
Disease control OngoingThis early-stage study tests two drugs, naporafenib and trametinib, in people with advanced solid tumors that have a specific RAS Q61X mutation and have stopped responding to other treatments. The goal is to see if the combination can shrink tumors and control the disease. About …
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo tested for tough-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called ERAS-601, alone or with other cancer treatments, in adults with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety, find the best dose, and see if the drug can shrink tum…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 18, 2026 12:09 UTC